Chelation treatments reduce cardiovascular events, such as heart attacks, and death in patients with diabetes but not in those who did not have diabetes, according to analyses of data from the National Institutes of Health-funded Trial to Assess Chelation Therapy (TACT). However, researchers say more research is needed before it’s known whether this promising finding leads to a treatment option.
Un viejo tratamiento utilizado por la medicina alternativa cobra nueva vida y es avalado por la ciencia al constatarse los beneficios que produce en los pacientes que padecen de diabetes y enfermedades de tipo cardiovascular.
| Title | Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction |
| Journal | Circ Cardiovasc Qual Outcomes |
| Authors | Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL |
| Year Published | 2014 |
| Link to article | |
| Link to abstract | |
Conclusions:
Post-myocardial infarction patients with diabetes mellitus aged ≥50 demonstrated a marked reduction in cardiovascular events with EDTA chelation. These findings support efforts to replicate these findings and define the mechanisms of benefit. However, they do not constitute sufficient evidence to indicate the routine use of chelation therapy for all post-myocardial infarction patients with diabetes mellitus.
| Title | Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial |
| Journal | JAMA |
| Authors | Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL, for the TACT Investigators. |
| Year Published | 2013 |
| Link to article | |
| Link to abstract | |
Conclusions and Relevance:
Among stable patients with a history of MI, use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes, many of which were revascularization procedures. These results provide evidence to guide further research but are not sufficient to support the routine use of chelation therapy for treatment of patients who have had an MI.
| Title | Design of the Trial to Assess Chelation Therapy (TACT) |
| Journal | American Heart Journal |
| Authors | Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL |
| Year Published | 2012 |
| Link to article | |
| Link to abstract | |
TACT is an National Institutes of Health-sponsored, randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial testing the benefits and risks of 40 infusions of a multicomponent disodium EDTA chelation solution compared with placebo and of an oral, high-dose multivitamin and mineral supplement. TACT has randomized and will follow up 1,708 patients for an average of approximately 4 years. The primary end point is a composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A 900-patient substudy will examine quality-of-life outcomes. The trial is designed to have >85% power to detect a 25% relative reduction in the primary end point for each treatment factor. Enrollment began in September 2003 and was completed in October 2010.